MACROGENICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
MACROGENICS, INC. (MGNX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $4.28 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-14
- MACROGENICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $7.17, a 28.08% decline year-over-year.
- MACROGENICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $9.97, a 9.69% decline year-over-year.
- MACROGENICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $11.04, a 3.66% decline year-over-year.
- MACROGENICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $11.46, a 30.59% decline year-over-year.
- MACROGENICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $8.54, a 25.35% decline from fiscal 2024.
- MACROGENICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $11.44, a 20.55% increase from fiscal 2023.
- MACROGENICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $9.49, a 40.01% decline from fiscal 2022.
- MACROGENICS, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $15.82, a 24.85% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.28 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | $7.17 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $8.54 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $9.23 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $9.55 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $9.97 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $11.44 10-K · filed 2025-03-20 | |||
| 2024-09-30 | $11.64 10-Q · filed 2024-11-05 | |||
| 2024-06-30 | $11.80 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $11.04 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $9.49 10-K · filed 2024-03-07 | |||
| 2023-09-30 | $9.78 10-Q · filed 2023-11-06 | |||
| 2023-06-30 | $10.05 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $11.46 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $15.82 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $16.05 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $16.32 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $16.51 10-Q · filed 2022-05-03 | |||
| 2021-12-31 | $21.05 10-K · filed 2022-02-24 | |||
| 2021-09-30 | $19.12 10-Q · filed 2021-11-02 | |||
| 2021-06-30 | $16.36 10-Q · filed 2021-07-29 | |||
| 2021-03-31 | $17.98 10-Q · filed 2021-04-29 | |||
| 2020-12-31 | $20.72 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $20.78 10-Q · filed 2020-11-04 | |||
| 2020-06-30 | $20.90 10-Q · filed 2020-07-31 | |||
| 2020-03-31 | $18.97 10-Q · filed 2020-05-05 | |||
| 2019-12-31 | $24.72 10-K · filed 2020-02-25 | |||
| 2019-09-30 | $23.44 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | $23.74 10-Q · filed 2019-07-31 | |||
| 2019-03-31 | $21.02 10-Q · filed 2019-05-01 | |||
| 2018-12-31 | $24.43 10-K · filed 2019-02-26 | |||
| 2018-09-30 | $24.25 10-Q · filed 2018-11-07 | |||
| 2018-06-30 | $23.50 10-Q · filed 2018-08-07 | |||
| 2018-03-31 | $20.90 10-Q · filed 2018-05-07 | |||
| 2017-12-31 | $24.26 10-K · filed 2018-02-27 | |||
| 2017-09-30 | $24.13 10-Q · filed 2017-11-08 | |||
| 2017-06-30 | $24.13 10-Q · filed 2017-08-02 | |||
| 2017-03-31 | $26.97 10-Q · filed 2017-05-03 | |||
| 2016-12-31 | $26.53 10-K · filed 2017-02-28 | |||
| 2016-09-30 | $26.50 10-Q · filed 2016-11-02 | |||
| 2016-06-30 | $28.70 10-Q · filed 2016-08-03 | |||
| 2016-03-31 | $29.07 10-Q · filed 2016-05-04 | |||
| 2015-12-31 | $23.44 10-K · filed 2016-02-29 | |||
| 2015-09-30 | $22.25 10-Q · filed 2015-11-04 | |||
| 2015-06-30 | $18.25 10-Q · filed 2015-08-05 | |||
| 2015-03-31 | $17.59 10-Q · filed 2015-05-06 | |||
| 2014-12-31 | $9.76 10-K · filed 2015-03-03 | |||
| 2014-09-30 | $7.42 10-Q · filed 2014-11-12 | |||
| 2014-06-30 | $3.32 10-Q · filed 2014-08-05 | |||
| 2014-03-31 | $3.36 10-Q · filed 2014-05-06 | |||
| 2013-12-31 | $1.11 10-K · filed 2014-03-20 | |||
| 2013-09-30 | $1.13 10-Q · filed 2013-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |